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■ SHORT COMMUNICATION ■
Introduction
Uterine myomas are one of the most common benign
tumors in women of reproductive age. In symptomatic
cases, treatment has traditionally been surgical, either
total hysterectomy (often via the abdominal route or
via laparoscopic assisted vaginal hysterectomy) if child-
bearing is no longer desired, or myomectomy if fertility 
is to be preserved; the latter may be complicated by 
significant blood loss and adhesion formation [1].
Gonadotropin-releasing hormone agonist (GnRH ago-
nist) therapy has been useful as an adjunct before
myomectomy or hysterectomy for uterine myoma [1,2].
Expulsion of a uterine submucosal myoma after admin-
istration of a GnRH agonist has previously been reported
[3], but surgical myoma removal was required. This
case is unique since the patient exhibited spontaneous
vaginal expulsion of the submucosal myoma and no
sequelae were noted thereafter.
Case Report
A 26-year-old woman without sexual exposure exhib-
ited heavy menstruation for approximately 2 years. The
patient’s past history was unremarkable and laboratory
data revealed normal electrolytes and hepatic–renal
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SUMMARY
Objective: Gonadotropin-releasing hormone agonist (GnRH agonist) therapy has been useful as an adjunct
before myomectomy or hysterectomy for uterine myoma.
Case Report: A 26-year-old woman without sexual exposure was diagnosed with a submucosal myoma and
treated with long-acting GnRH agonist. This patient exhibited heavy menstruation and severe anemia for 2 years
and consulted our outpatient department. Transabdominal ultrasound demonstrated a 3.5-cm submucosal
myoma within the endometrial cavity. The patient showed a marked suppression of serum estradiol concentrations
throughout the treatment (< 20 pg/mL at the second dose injection). The volume of the uterus and uterine
myoma decreased to two-thirds of the original size at the end of the second dose injection. However, a sudden
onset of severe abdominal cramping pain occurred on the 76th day and a ping-pong sized mass was expelled
from the vagina. She visited our outpatient department for evaluation, where ultrasound failed to detect the
previous submucosal uterine myoma. A 3-year follow-up has been uneventful.
Conclusion: Spontaneous expulsion of submucosal myomas might occur after the administration of GnRH
agonist; hence, it may be an acceptable alternative for symptomatic females without sexual exposure. [Taiwanese
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profile. However, hemoglobin 5.6 g/dL was noted (nor-
mal, 12–14 g/dL). Transabdominal ultrasound demon-
strated a 3.5-cm submucosal myoma. Initial therapy
included a 12-day regimen of dehydroxyprogesterone
(Provera®) 10 mg daily from menstrual day 16 to 27 
as well as ferrum replacement. After 3 months, heavy
menstruation and anemia persisted; oral pills were sug-
gested, but the patient refused. After a detailed dis-
cussion and considering the potential risk of surgical
intervention, long-acting GnRH agonist was suggested.
The patient reached a menopausal state after the
first dose of GnRH agonist was administered, without
significant menopausal symptoms or signs. Regular
follow-up revealed that the size of the submucosal
myoma had decreased to two-thirds the original size
after the second-dose injection. During the course of
treatment, the patient suffered from acute abdominal
cramping pain on the 76th day after receiving the first-
dose injection and a ping-pong sized mass was expelled
per vagina. She visited our outpatient clinic and trans-
abdominal ultrasound failed to detect the previous uter-
ine myoma. She had normal menstruation for 3 years
without any evidence of recurrent uterine myoma.
Discussion
Women without sexual exposure who exhibit heavy
menstruation due to submucosal uterine myomas are
sometimes difficult to deal with because of their unwill-
ingness to undergo surgery (myomectomy, total hys-
terectomy, hysteroscopic myomectomy). The value of a
low-dose combination of estrogen and progesterone in
managing uterine myoma is still controversial because
study results are not consistent [4]. Oral pills may be an
alternative, depending on the patient’s willingness.
The association between myomas and estrogen-
dependency is well established [5–8]. It has been reported
that myomas are a hormone-dependent disease, and
menopause often causes regression of the myoma.
Since the patient had no previous sexual exposure and
was diagnosed with a submucosal myoma with severe
anemia, we considered using the strategy of medical
castration in an attempt to relieve her symptoms and
signs. The advantages of GnRH agonist therapy are 
that it constitutes a medical, reversible, and noninvasive
therapeutic option that can be used for GnRH- and/or
estrogen-dependent tumors [9–12].
GnRH agonist therapy is suggested to facilitate sur-
gery by shrinking tumor size and decreasing blood loss.
In addition, estrogen–progestin add-back regimens in
using GnRH agonist treatment for women with uterine
myoma were confirmed based on efficacy and safety
parameters assessed [13]. For the purpose of long-term
use in women with symptomatic uterine myoma, GnRH
agonist/steroid add-back regimens might be a good
choice [13].
What caused the spontaneous expulsion of the
uterine myoma in this patient is not clear and is difficult
to define. A possible explanation may be rapid tumor
shrinkage with discordance between the submucosal
myoma and the surrounding tissue. Of utmost impor-
tance, the size of the uterine myoma was relatively small
(shrinkage to 2 cm during treatment). These factors may
have contributed to the unusual event of spontaneous
expulsion of the uterine myoma.
In conclusion, administration of GnRH agonist in
patients without sexual exposure could be an alterna-
tive choice in the treatment of submucosal myomas.
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